LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Priority III: top 10 rapid review methodology research priorities identified using a James Lind Alliance Priority Setting Partnership.

    Beecher, Claire / Toomey, Elaine / Maeso, Beccy / Whiting, Caroline / Stewart, Derek C / Worrall, Andrew / Elliott, Jim / Smith, Maureen / Tierney, Theresa / Blackwood, Bronagh / Maguire, Teresa / Kampman, Melissa / Ling, Benny / Gill, Catherine / Healy, Patricia / Houghton, Catherine / Booth, Andrew / Garritty, Chantelle / Thomas, James /
    Tricco, Andrea C / Burke, Nikita N / Keenan, Ciara / Devane, Declan

    Journal of clinical epidemiology

    2022  Volume 151, Page(s) 151–160

    Abstract: Objectives: A rapid review is a form of evidence synthesis considered a resource-efficient alternative to the conventional systematic review. Despite a dramatic rise in the number of rapid reviews commissioned and conducted in response to the ... ...

    Abstract Objectives: A rapid review is a form of evidence synthesis considered a resource-efficient alternative to the conventional systematic review. Despite a dramatic rise in the number of rapid reviews commissioned and conducted in response to the coronavirus disease 2019 pandemic, published evidence on the optimal methods of planning, doing, and sharing the results of these reviews is lacking. The Priority III study aimed to identify the top 10 unanswered questions on rapid review methodology to be addressed by future research.
    Study design and setting: A modified James Lind Alliance Priority Setting Partnership approach was adopted. This approach used two online surveys and a virtual prioritization workshop with patients and the public, reviewers, researchers, clinicians, policymakers, and funders to identify and prioritize unanswered questions.
    Results: Patients and the public, researchers, reviewers, clinicians, policymakers, and funders identified and prioritized the top 10 unanswered research questions about rapid review methodology. Priorities were identified throughout the entire review process, from stakeholder involvement and formulating the question, to the methods of a systematic review that are appropriate to use, through to the dissemination of results.
    Conclusion: The results of the Priority III study will inform the future research agenda on rapid review methodology. We hope this will enhance the quality of evidence produced by rapid reviews, which will ultimately inform decision-making in the context of healthcare.
    Language English
    Publishing date 2022-08-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 639306-8
    ISSN 1878-5921 ; 0895-4356
    ISSN (online) 1878-5921
    ISSN 0895-4356
    DOI 10.1016/j.jclinepi.2022.08.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.206: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: What are the most important unanswered research questions on rapid review methodology? A James Lind Alliance research methodology Priority Setting Partnership: the Priority III study protocol.

    Beecher, Claire / Toomey, Elaine / Maeso, Beccy / Whiting, Caroline / Stewart, Derek C / Worrall, Andrew / Elliott, Jim / Smith, Maureen / Tierney, Theresa / Blackwood, Bronagh / Maguire, Teresa / Kampman, Melissa / Ling, Benny / Gravel, Christopher / Gill, Catherine / Healy, Patricia / Houghton, Catherine / Booth, Andrew / Garritty, Chantelle /
    Thomas, James / Tricco, Andrea C / Burke, Nikita N / Keenan, Ciara / Westmore, Matthew / Devane, Declan

    HRB open research

    2021  Volume 4, Page(s) 80

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2021-11-18
    Publishing country Ireland
    Document type Journal Article
    ISSN 2515-4826
    ISSN (online) 2515-4826
    DOI 10.12688/hrbopenres.13321.2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: A Decrease in Neural Sialyltransferase Activity in Alzheimer’s Disease

    Maguire, Teresa M. / Breen, Kieran C.

    Dementia and Geriatric Cognitive Disorders

    1995  Volume 6, Issue 4, Page(s) 185–190

    Abstract: The activities of both a particulate and soluble form of the sialyltransferase enzyme have been examined in post-mortem brain samples from Alzheimer's disease patients and age-matched controls. There was a considerable decrease in the activity of both ... ...

    Abstract The activities of both a particulate and soluble form of the sialyltransferase enzyme have been examined in post-mortem brain samples from Alzheimer's disease patients and age-matched controls. There was a considerable decrease in the activity of both the soluble and membrane-bound forms of the enzyme in the frontal and temporal cortical lobes, although no change was observed in the hippocampus. There was, however, no change in activity of the Golgi marker enzyme thiamine pyrophosphatase. Therefore, it is suggested that the decrease in sialyltransferase enzyme activity may be a specific biochemical event associated with the AD-like neurodegeneration.
    Keywords Sialyltransferase ; Alzheimer's disease ; Glycosylation ; Sialic acid
    Language English
    Publisher S. Karger AG
    Publishing place Basel
    Publishing country Switzerland
    Document type Article ; Online
    ZDB-ID 1026007-9
    ISSN 1421-9824 ; 1420-8008 ; 1013-7424 ; 1420-8008 ; 1013-7424
    ISSN (online) 1421-9824
    ISSN 1420-8008 ; 1013-7424
    DOI 10.1159/000106944
    Database Karger publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2866: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.

    Pan, Hongchao / Peto, Richard / Henao-Restrepo, Ana-Maria / Preziosi, Marie-Pierre / Sathiyamoorthy, Vasee / Abdool Karim, Quarraisha / Alejandria, Marissa M / Hernández García, César / Kieny, Marie-Paule / Malekzadeh, Reza / Murthy, Srinivas / Reddy, K Srinath / Roses Periago, Mirta / Abi Hanna, Pierre / Ader, Florence / Al-Bader, Abdullah M / Alhasawi, Almonther / Allum, Emma / Alotaibi, Athari /
    Alvarez-Moreno, Carlos A / Appadoo, Sheila / Asiri, Abdullah / Aukrust, Pål / Barratt-Due, Andreas / Bellani, Samir / Branca, Mattia / Cappel-Porter, Heike B C / Cerrato, Nery / Chow, Ting S / Como, Najada / Eustace, Joe / García, Patricia J / Godbole, Sheela / Gotuzzo, Eduardo / Griskevicius, Laimonas / Hamra, Rasha / Hassan, Mariam / Hassany, Mohamed / Hutton, David / Irmansyah, Irmansyah / Jancoriene, Ligita / Kirwan, Jana / Kumar, Suresh / Lennon, Peter / Lopardo, Gustavo / Lydon, Patrick / Magrini, Nicola / Maguire, Teresa / Manevska, Suzana / Manuel, Oriol / McGinty, Sibylle / Medina, Marco T / Mesa Rubio, María L / Miranda-Montoya, Maria C / Nel, Jeremy / Nunes, Estevao P / Perola, Markus / Portolés, Antonio / Rasmin, Menaldi R / Raza, Aun / Rees, Helen / Reges, Paula P S / Rogers, Chris A / Salami, Kolawole / Salvadori, Marina I / Sinani, Narvina / Sterne, Jonathan A C / Stevanovikj, Milena / Tacconelli, Evelina / Tikkinen, Kari A O / Trelle, Sven / Zaid, Hala / Røttingen, John-Arne / Swaminathan, Soumya

    The New England journal of medicine

    2020  Volume 384, Issue 6, Page(s) 497–511

    Abstract: Background: World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19).!# ...

    Abstract Background: World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19).
    Methods: We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard of care). The intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its control (drug available but patient assigned to the same care without that drug). Rate ratios for death were calculated with stratification according to age and status regarding mechanical ventilation at trial entry.
    Results: At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan-Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P = 0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P = 0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P = 0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P = 0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration.
    Conclusions: These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov number, NCT04315948.).
    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Aged ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; COVID-19/mortality ; Drug Therapy, Combination ; Female ; Hospital Mortality ; Hospitalization ; Humans ; Hydroxychloroquine/therapeutic use ; Intention to Treat Analysis ; Interferon beta-1a/therapeutic use ; Kaplan-Meier Estimate ; Length of Stay ; Lopinavir/therapeutic use ; Male ; Middle Aged ; Respiration, Artificial ; Treatment Failure ; COVID-19 Drug Treatment
    Chemical Substances Antiviral Agents ; Lopinavir (2494G1JF75) ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Hydroxychloroquine (4QWG6N8QKH) ; Alanine (OF5P57N2ZX) ; Interferon beta-1a (XRO4566Q4R)
    Language English
    Publishing date 2020-12-02
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa2023184
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Mammaglobin a: a promising marker for breast cancer.

    O'Brien, Neil / Maguire, Teresa M / O'Donovan, Norma / Lynch, Niamh / Hill, Arnold D K / McDermott, Enda / O'Higgins, Niall / Duffy, Michael J

    Clinical chemistry

    2002  Volume 48, Issue 8, Page(s) 1362–1364

    MeSH term(s) Biomarkers, Tumor/analysis ; Breast/chemistry ; Breast Neoplasms/diagnosis ; Carrier Proteins/analysis ; Female ; Fibroadenoma/chemistry ; Globins/analysis ; Humans ; Mammaglobin A ; Myelin Proteins ; Neoplasm Proteins/analysis ; Organ Specificity ; Proteolipids ; Reverse Transcriptase Polymerase Chain Reaction ; Secretoglobins ; Sensitivity and Specificity ; Uteroglobin/analysis
    Chemical Substances Biomarkers, Tumor ; Carrier Proteins ; Mammaglobin A ; Myelin Proteins ; Neoplasm Proteins ; Proteolipids ; SCGB2A2 protein, human ; Secretoglobins ; Globins (9004-22-2) ; Uteroglobin (9060-09-7)
    Language English
    Publishing date 2002-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.171: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top